Roivant reports positive chronic data for RVT-3101 in ulcerative colitis, efficacy improved from induction at week 56

Roivant Sciences Ltd.

At expected Phase 3 dose, Clinical Remission 36% at week 56 vs 29% at week 14; Endoscopic Improvement 50% vs 36%.
In biomarker-positive patients, Clinical Remission 43% at week 56 (33% at week 14), Endoscopic Improvement 64% (47%).
Favorable safety profile through 56 weeks; 0% neutralizing antibodies at week 56 at Phase 3 dose.
First long-duration data for an anti-TL1A antibody; results support Phase 3 potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.